Published Year: 2021
Global Cell and Gene Therapy Manufacturing QC Market: Focus on Products and Services, Process, Analy
The global market for cell and gene therapy manufacturing QC is predicted to grow at a CAGR of...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Inclusion and Exclusion
1.2 Scope of Work
1.3 Key Questions Answered in the Report
2.1 Primary Data Sources
2.2 Secondary Data Sources
2.3 Market Estimation Model
2.4 Criteria for Company Profiling
3.1 Clinical Importance of Regenerative Medicine
3.2 Market Footprint
3.3 Impact of COVID-19
4.1 Impact Analysis
4.2 Market Drivers
4.2.1 Increasing Consolidation in the Regenerative Medicines Market
4.2.2 Rising Number of Clinical Trials
4.2.3 Favorable Regulatory Environment
4.2.4 Rising Awareness for Stem Cell Therapeutics
4.3 Market Restraints
4.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
4.3.2 Exorbitant Cost of Next-Generation Therapies
4.4 Opportunities
4.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
4.4.2 Multiple Investments in Expansion of cGMP Units
4.4.3 Innovations in Regenerative Medicine
5.1 Overview
5.2 Legal and Regulatory Framework in the U.S.
5.2.1 Cell and Gene Therapy
5.2.1.1 Cell and Gene Therapy Manufacturing QC
5.2.1.1.1 Product Testing
5.2.1.1.1.1 Microbial Testing
5.2.1.1.1.2 Identity
5.2.1.1.1.3 Purity
5.2.1.1.1.4 Potency
5.2.1.1.1.5 Viability
5.2.1.1.1.6 Cell Number/Dose
5.2.2 Stem Cell Therapy
5.2.3 Tissue-Engineered Products
5.3 Legal and Regulatory Framework in Europe
5.4 Legal and Regulatory Framework in Asia-Pacific
5.4.1 China
5.4.2 Japan
6.1 Overview
6.2 Synergistic Activities
6.3 Product Approval
6.4 Mergers and Acquisitions
6.5 Business Expansion and Funding
6.6 Product Launches and Upgradations
6.7 Market Share Analysis, 2019-2020
6.7.1 Market Share Analysis for Global Regenerative Medicines Market (Tissue Engineering), 2019-2020
6.7.2 Market Share Analysis for Global Regenerative Medicines Market (Cell and Gene Therapy), 2019-2020
6.7.3 Market Share Analysis for Global Regenerative Medicines Market (Stem Cell Therapy), 2019-2020
6.8 Growth Share Analysis
6.8.1 Growth Share Analysis (by Company)
6.8.2 Growth Share Analysis (by Product)
6.8.3 Growth Share Analysis (by Application)
7.1 Overview
7.2 Tissue Engineering
7.2.1 Allogeneic Tissue
7.2.2 Autologous Tissue
7.2.3 Xenogeneic Tissue
7.2.4 Synthetic Tissue
7.2.5 Other Tissues
7.3 Stem Cells
7.3.1 Stem Cell Services
7.3.2 Stem Cell Therapy
7.4 Cell and Gene Therapy
7.4.1 Cell Therapy
7.4.1.1 Cell Therapy (by Type)
7.4.2 Gene Therapy
8.1 Overview
8.2 Orthopedic and Musculoskeletal
8.3 Oncology
8.4 Wound Care
8.5 Cardiology
8.6 Immunology
8.7 Dermatology
8.8 Other Applications
9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 Italy
9.3.4 U.K.
9.3.5 Spain
9.3.6 Russia
9.3.7 Netherlands
9.3.8 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 South Korea
9.4.4 Australia
9.4.5 India
9.4.6 Singapore
9.4.7 Rest-of-Asia-Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest-of-Latin America
9.6 Rest-of-the-World (RoW)
10.1 Overview
10.2 AbbVie, Inc.
10.2.1 Company Overview
10.2.2 Role of AbbVie, Inc. in Global Regenerative Medicines Market
10.2.3 Financials
10.2.4 Key Insights About Financial Health of the Company
10.2.5 SWOT Analysis
10.3 Baxter International Inc.
10.3.1 Company Overview
10.3.2 Role of Baxter International Inc. in Global Regenerative Medicines Market
10.3.3 Financials
10.3.4 Key Insights About Financial Health of the Company
10.3.5 SWOT Analysis
10.4 Becton, Dickinson and Company
10.4.1 Company Overview
10.4.2 Role of Becton, Dickinson and Company in the Global Regenerative Medicines Market
10.4.3 Financials
10.4.4 Key Insights About Financial Health of the Company
10.4.5 SWOT Analysis
10.5 Dendreon Pharmaceuticals LLC.
10.5.1 Company Overview
10.5.2 Role of Dendreon Pharmaceuticals LLC. in the Global Regenerative Medicines Market
10.5.3 SWOT Analysis
10.6 F. Hoffmann-La Roche Ltd
10.6.1 Company Overview
10.6.2 Role of F. Hoffmann-La Roche Ltd. in the Global Regenerative Medicines Market
10.6.3 Financials
10.6.4 Key Insights About Financial Health of the Company
10.6.5 SWOT Analysis
10.7 FUJIFILM Holdings Corporation
10.7.1 Company Overview
10.7.2 Role of FUJIFILM Holdings Corporation in the Global Regenerative Medicines Market
10.7.3 Financials
10.7.4 Key Insights About Financial Health of the Company
10.7.5 SWOT Analysis
10.8 Gilead Sciences, Inc.
10.8.1 Company Overview
10.8.2 Role of Gilead Sciences, Inc. in the Global Regenerative Medicines Market
10.8.3 Financials
10.8.4 Key Insights About Financial Health of the Company
10.8.5 SWOT Analysis
10.9 Integra LifeSciences Holdings Corporation
10.9.1 Company Overview
10.9.2 Role of Integra LifeSciences Holdings Corporation in Global Regenerative Medicines Market
10.9.3 Financials
10.9.4 Key Insights About Financial Health of the Company
10.9.5 SWOT Analysis
10.10 Johnson & Johnson
10.10.1 Company Overview
10.10.2 Role of Johnson & Johnson in the Global Regenerative Medicines Market
10.10.3 Financials
10.10.4 Key Insights About Financial Health of the Company
10.10.5 SWOT Analysis
10.11 Medtronic plc
10.11.1 Company Overview
10.11.2 Role of Medtronic plc in the Global Regenerative Medicines Market
10.11.3 Financials
10.11.4 Key Insights About Financial Health of the Company
10.11.5 SWOT Analysis
10.12 Mesoblast Ltd
10.12.1 Company Overview
10.12.2 Role of Mesoblast Ltd in the Global Regenerative Medicines Market
10.12.3 Financials
10.12.4 Key Insights About Financial Health of the Company
10.12.5 SWOT Analysis
10.13 Novartis International AG
10.13.1 Company Overview
10.13.2 Role of Novartis International AG in the Global Regenerative Medicines Market
10.13.3 Financials
10.13.4 Key Insights About Financial Health of the Company
10.13.5 SWOT Analysis
10.14 NuVasive, Inc.
10.14.1 Company Overview
10.14.2 Role of NuVasive, Inc. in the Global Regenerative Medicines Market
10.14.3 Financials
10.14.4 Key Insights About Financial Health of the Company
10.14.5 SWOT Analysis
10.15 Organogenesis Holdings Inc.
10.15.1 Company Overview
10.15.2 Role of Organogenesis Holdings, Inc. in the Global Regenerative Medicines Market
10.15.3 Financials
10.15.4 Key Insights About the Financial Health of the Company
10.15.5 SWOT Analysis
10.16 Smith & Nephew plc
10.16.1 Company Overview
10.16.2 Role of Smith & Nephew plc in the Global Regenerative Medicines Market
10.16.3 Financials
10.16.4 Key Insights About Financial Health of the Company
10.16.5 SWOT Analysis
10.17 Stryker Corporation
10.17.1 Company Overview
10.17.2 Role of Stryker Corporation in the Global Regenerative Medicines Market
10.17.3 Financials
10.17.4 Key Insights About Financial Health of the Company
10.17.5 SWOT Analysis
10.18 Vericel Corporation
10.18.1 Company Overview
10.18.2 Role of Vericel Corporation in the Global Regenerative Medicines Market
10.18.3 Financials
10.18.4 Key Insights About Financial Health of the Company
10.18.5 SWOT Analysis
10.19 Zimmer Biomet Holdings, Inc.
10.19.1 Company Overview
10.19.2 Role of Zimmer Biomet Holdings, Inc. in the Global Regenerative Medicines Market
10.19.3 Financials
10.19.4 Key Insights About Financial Health of the Company
10.19.5 SWOT Analysis
Table 3.1: Key Products of Cell and Gene Therapy Market
Table 4.1: Impact Analysis
Table 4.2: Key Cell and Gene Therapies with FDA Expedited Review
Table 4.3: Range of Cost for Regenerative Therapies
Table 7.1: List of Key Products
Table 7.2: List of Key Products
Table 7.3: List of Key Products
Table 7.4: List of Key Products
Table 7.5: List of Key Products
Table 7.6: List of Key Services
Table 7.7: List of Key Products
Table 7.8: List of Key Products
Table 7.9: List of Key Products
Figure 1: Global Clinical Landscape for Regenerative Medicine, 2019
Figure 2: Impact Analysis on the Global Regenerative Medicines Market
Figure 3: Global Regenerative Medicines Market (by Product), $Million, 2019 and 2030
Figure 4: Global Regenerative Medicines Market (by Application), $Million, 2019 and 2030
Figure 5: Global Regenerative Medicines Market (by Region), Market Snapshot
Figure 6: Global Regenerative Medicines Market (by Companies Profiled), Market Snapshot
Figure 1.1: Global Regenerative Medicines Market Segmentation
Figure 2.1: Bottom-Up Approach (Segment-Wise Analysis)
Figure 2.2: Top-Down Approach (Segment-Wise Analysis)
Figure 3.1: Global Regenerative Medicines Market, $Million, 2019-2030
Figure 3.2: Impact of COVID-19 on Global Regenerative Medicines Market
Figure 4.1: Number of Clinical Trials for ATMP (by Phase), 2019
Figure 6.1: Share of Key Developments and Strategies, January 2017-February 2021
Figure 6.2: Share of Synergistic Activities, January 2017-February 2021
Figure 6.3: Share of Product Approvals (by Company), January 2017-February 2020
Figure 6.4: Share of Mergers and Acquisitions (by Company), January 2017-February 2021
Figure 6.4: Business Expansion Activities Share, January 2011-February 2021
Figure 6.5: Share of Product Launches and Upgradations, January 2017-February 2021
Figure 6.6: Market Share Analysis for Global Regenerative Medicines Market (Tissue Engineering), 2019 and 2020
Figure 6.7: Market Share Analysis for Global Regenerative Medicines Market (Cell and Gene Therapy), 2019 and 2020
Figure 6.8: Market Share Analysis for Global Regenerative Medicines Market (Stem Cell Therapy), 2019 and 2020
Figure 6.9: Growth Share Analysis for Global Regenerative Medicines Market (by Company), 2020
Figure 6.10: Growth Share Analysis for Global Regenerative Medicines Market (by Product), 2020-2030
Figure 6.11: Growth Share Analysis for Global Regenerative Medicines Market (by Application), 2020-2030
Figure 7.1: Global Regenerative Medicines Market (by Product Type), $Million, 2019 and 2030
Figure 7.2: Global Regenerative Medicines Market (by Tissue Engineering), $Million, 2019-2030
Figure 7.3: Global Regenerative Medicines Market (Allogeneic Tissue), $Million, 2019-2030
Figure 7.4: Global Regenerative Medicines Market (Autologous Tissue), $Million, 2019-2030
Figure 7.5: Global Regenerative Medicines Market (Xenogeneic Tissue), $Million, 2019-2030
Figure 7.6: Global Regenerative Medicines Market (Synthetic Tissue), $Million, 2019-2030
Figure 7.7: Global Regenerative Medicines Market (Other Tissues), $Million, 2019-2030
Figure 7.8: Global Regenerative Medicines Market (by Stem Cells), $Million, 2019-2030
Figure 7.9: Global Regenerative Medicines Market (Stem Cell Services), $Million, 2019-2030
Figure 7.10: Global Regenerative Medicines Market (Stem Cell Therapy), $Million, 2019-2030
Figure 7.11: Global Regenerative Medicines Market (by Cell and Gene Therapy), $Million, 2019-2030
Figure 7.12: Global Regenerative Medicines Market (by Cell Therapy), $Million, 2019-2030
Figure 7.13: Global Regenerative Medicines Market (by Cell Therapy Type), $Million, 2019 and 2030
Figure 7.14: Global Regenerative Medicines Market (Gene Therapy), $Million, 2019-2030
Figure 8.1: Global Regenerative Medicines Market (by Application), $Million, 2019 and 2030
Figure 8.2: Global Regenerative Medicines Market (Orthopedic and Musculoskeletal), $Million, 2019-2030
Figure 8.3: Global Regenerative Medicines Market (Oncology), $Million, 2019-2030
Figure 8.4: Global Regenerative Medicines Market (Wound Care), $Million, 2019-2030
Figure 8.5: Global Regenerative Medicines Market (Cardiology), $Million, 2019-2030
Figure 8.6: Global Regenerative Medicines Market (Immunology), $Million, 2019-2030
Figure 8.7: Global Regenerative Medicines Market (Dermatology), $Million, 2019-2030
Figure 8.8: Global Regenerative Medicines Market (Other Applications), $Million, 2019-2030
Figure 9.1: Global Regenerative Medicines Market (by Region), Market Snapshot
Figure 9.2: North America: Market Dynamics
Figure 9.3: North America Regenerative Medicines Market, $Million, 2019-2030
Figure 9.4: North America Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
Figure 9.5: U.S. Regenerative Medicines Market, $Million, 2019-2030
Figure 9.6: U.S. Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.7: Canada Regenerative Medicines Market, $Million, 2019-2030
Figure 9.8: Canada Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.9: Europe: Market Dynamics
Figure 9.10: Europe Regenerative Medicines Market, $Million, 2019-2030
Figure 9.11: Europe Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
Figure 9.12: Germany Regenerative Medicines Market, $Million, 2019-2030
Figure 9.13: Germany Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.14: France Regenerative Medicines Market, $Million, 2019-2030
Figure 9.15: France Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.16: Italy Regenerative Medicines Market, $Million, 2019-2030
Figure 9.17: Italy Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.18: U.K. Regenerative Medicines Market, $Million, 2019-2030
Figure 9.19: U.K. Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.20: Spain Regenerative Medicines Market, $Million, 2019-2030
Figure 9.21: Spain Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.22: Russia Regenerative Medicines Market, $Million, 2019-2030
Figure 9.23: Russia Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.24: Netherlands Regenerative Medicines Market, $Million, 2019-2030
Figure 9.25: Netherlands Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.26: Rest-of-Europe Regenerative Medicines Market, $Million, 2019-2030
Figure 9.27: Rest-of-Europe Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.28: Asia-Pacific: Market Dynamics
Figure 9.29: Asia-Pacific Regenerative Medicines Market, $Million, 2019-2030
Figure 9.30: Asia-Pacific Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
Figure 9.31: China Regenerative Medicines Market, $Million, 2019-2030
Figure 9.32: China Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.33: Japan Regenerative Medicines Market, $Million, 2019-2030
Figure 9.34: Japan Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.35: South Korea Regenerative Medicines Market, $Million, 2019-2030
Figure 9.36: South Korea Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.37: Australia Regenerative Medicines Market, $Million, 2019-2030
Figure 9.38: Australia Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.39: India Regenerative Medicines Market, $Million, 2019-2030
Figure 9.40: India Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.41: Singapore Regenerative Medicines Market, $Million, 2019-2030
Figure 9.42: Singapore Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.43: Rest-of-Asia-Pacific Regenerative Medicines Market, $Million, 2019-2030
Figure 9.44: Rest-of-Asia-Pacific Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.45: Latin America: Market Dynamics
Figure 9.46: Latin America Regenerative Medicines Market, $Million, 2019-2030
Figure 9.47: Latin America Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
Figure 9.48: Brazil Regenerative Medicines Market, $Million, 2019-2030
Figure 9.49: Brazil Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.50: Mexico Regenerative Medicines Market, $Million, 2019-2030
Figure 9.51: Mexico Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.52: Rest-of-Latin America Regenerative Medicines Market, $Million, 2019-2030
Figure 9.53: Rest-of-Latin America Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.54: Rest-of-the-World Regenerative Medicines Market, $Million, 2019-2030
Figure 10.1: Total Number of Companies Profiled
Figure 10.2: AbbVie, Inc.: Overall Product Portfolio
Figure 10.3: AbbVie, Inc.: Overall Financials, 2018-2020
Figure 10.4: AbbVie, Inc.: Revenue (by Segment), 2018-2020
Figure 10.5: AbbVie, Inc.: Revenue (by Region), 2018-2020
Figure 10.6: AbbVie, Inc.: R&D Expenditure, 2018-2020
Figure 10.7: AbbVie, Inc.: SWOT Analysis
Figure 10.8: Baxter International Inc.: Overall Product Portfolio
Figure 10.9: Baxter International Inc.: Overall Financials, 2018-2020
Figure 10.10: Baxter International Inc.: Revenue (by Segment), 2018-2020
Figure 10.11: Baxter International Inc.: Revenue (by Region), 2018-2020
Figure 10.12: Baxter International Inc.: R&D Expenditure, 2018-2020
Figure 10.13: bioMérieux SA: SWOT Analysis
Figure 10.14: Becton, Dickinson and Company: Overall Service Portfolio
Figure 10.15: Becton, Dickinson and Company.: Overall Financials, 2018-2020
Figure 10.16: Becton, Dickinson and Company: Revenue (by Segment), 2018-2020
Figure 10.17: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
Figure 10.18: Becton, Dickinson and Company: R&D Expenditure, 2018-2020
Figure 10.19: Becton, Dickinson and Company: SWOT Analysis
Figure 10.20: Dendreon Pharmaceuticals LLC.: Product Portfolio
Figure 10.21: Dendreon Pharmaceuticals LLC.: SWOT Analysis
Figure 10.22: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
Figure 10.23: F. Hoffmann-La Roche Ltd.: Pipeline Portfolio
Figure 10.24: F. Hoffmann-La Roche Ltd.: Overall Financials, 2018-2020
Figure 10.25: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), 2018-2020
Figure 10.26: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020
Figure 10.27: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
Figure 10.28: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 10.29: FUJIFILM Holdings Corporation: Overall Product Portfolio
Figure 10.30: FUJIFILM Holdings Corporation: Overall Financials, 2017-2019
Figure 10.31: FUJIFILM Holdings Corporation: Revenue (by Segment), 2017-2019
Figure 10.32: FUJIFILM Holdings Corporation: Revenue (by Region), 2017-2019
Figure 10.33: FUJIFILM Holdings Corporation: R&D Expenditure, 2017-2019
Figure 10.34: FUJIFILM Holdings Corporation: SWOT Analysis
Figure 10.35: Gilead Sciences, Inc.: Product Portfolio
Figure 10.36: Gilead Sciences, Inc.: Pipeline Product Portfolio
Figure 10.37: Gilead Sciences, Inc.: Overall Financials, 2018-2020
Figure 10.38: Gilead Sciences, Inc.: Revenue (by Segment), 2018-2020
Figure 10.39: Gilead Sciences, Inc.: Revenue (by Region), 2018-2020
Figure 10.40: Gilead Sciences, Inc.: R&D Expenditure, 2018-2020
Figure 10.41: Gilead Sciences, Inc.: SWOT Analysis
Figure 10.42: Integra LifeSciences Holdings Corporation: Overall Product Portfolio
Figure 10.43: Integra LifeSciences Holdings Corporation: Overall Financials, 2018-2020
Figure 10.44: Integra LifeSciences Holdings Corporation: Revenue (by Segment), 2018-2020
Figure 10.45: Integra LifeSciences Holdings Corporation: Revenue (by Region), 2018-2020
Figure 10.46: Integra LifeSciences Holdings Corporation: R&D Expenditure, 2018-2020
Figure 10.47: Integra LifeSciences Holdings Corporation: SWOT Analysis
Figure 10.48: Johnson & Johnson: Product Portfolio
Figure 10.49: Johnson & Johnson: Overall Financials, 2018-2020
Figure 10.50: Johnson & Johnson: Revenue (by Segment), 2018-2020
Figure 10.51: Johnson & Johnson: Revenue (by Region), 2018-2020
Figure 10.52: Johnson & Johnson: R&D Expenditure, 2018-2020
Figure 10.53: Johnson & Johnson: SWOT Analysis
Figure 10.54: Medtronic plc: Product Portfolio
Figure 10.55: Medtronic plc: Overall Financials, 2018-2020
Figure 10.56: Medtronic plc: Revenue (by Segment), 2018-2020
Figure 10.57: Medtronic plc: Revenue (by Restorative Therapies Group), 2018-2020
Figure 10.58: Medtronic plc: Revenue (by Region), 2018-2020
Figure 10.59: Medtronic plc: R&D Expenditure, 2018-2020
Figure 10.60: Medtronic plc: SWOT Analysis
Figure 10.61: Mesoblast Ltd.: Product Portfolio
Figure 10.62: Mesoblast Ltd.: Product Portfolio
Figure 10.62: Mesoblast Ltd: Overall Financials, 2018-2020
Figure 10.63: Mesoblast Ltd: Revenue (by Segment), 2018-2020
Figure 10.64: Mesoblast Ltd: R&D Expenditure, 2018-2020
Figure 10.65: Mesoblast Ltd: SWOT Analysis
Figure 10.66: Novartis International AG: Product Portfolio
Figure 10.67: Novartis International AG: Pipeline Product Portfolio
Figure 10.68: Novartis International AG.: Overall Financials, 2018-2020
Figure 10.69: Novartis International AG: Revenue (by Segment), 2018-2020
Figure 10.70: Novartis International AG: Revenue (by Region), 2018-2020
Figure 10.71: Novartis International AG: R&D Expenditure, 2018-2020
Figure 10.72: Novartis International AG: SWOT Analysis
Figure 10.73: NuVasive, Inc.: Product Portfolio
Figure 10.74: NuVasive, Inc.: Overall Financials, 2018-2020
Figure 10.75: NuVasive, Inc.: Revenue (by Segment), 2018-2020
Figure 10.76: NuVasive, Inc.: Revenue (by Region), 2018-2020
Figure 10.77: NuVasive, Inc.: R&D Expenditure, 2018-2020
Figure 10.78: NuVasive, Inc.: SWOT Analysis
Figure 10.79: Organogenesis Holdings Inc.: Product Portfolio
Figure 10.80: Organogenesis Holdings Inc.: Overall Financials, 2017-2019
Figure 10.81: Organogenesis Holdings Inc.: Revenue (by Segment), 2017-2019
Figure 10.82: Organogenesis Holdings Inc.: R&D Expenditure, 2017-2019
Figure 10.83: Organogenesis Holdings Inc.: SWOT Analysis
Figure 10.84: Smith & Nephew plc: Product Portfolio
Figure 10.85: Smith & Nephew plc: Overall Financials, 2018-2020
Figure 10.86: Smith & Nephew plc: Revenue (by Segment), 2018-2020
Figure 10.87: Smith & Nephew plc: Revenue (by Region), 2018-2020
Figure 10.88: Smith & Nephew plc: R&D Expenditure, 2018-2020
Figure 10.89: Smith & Nephew plc: SWOT Analysis
Figure 10.90: Stryker Corporation: Product Portfolio
Figure 10.91: Stryker Corporation: Overall Financials, 2018-2020
Figure 10.92: Stryker Corporation: Revenue (by Segment), 2018-2020
Figure 10.93: Stryker Corporation: Revenue (by Region), 2018-2020
Figure 10.94: Stryker Corporation: R&D Expenditure, 2018-2020
Figure 10.95: Stryker Corporation: SWOT Analysis
Figure 10.96: Vericel Corporation: Product Portfolio
Figure 10.97: Vericel Corporation: Overall Financials, 2018-2020
Figure 10.98: Vericel Corporation: Revenue (by Segment), 2018-2020
Figure 10.99: Vericel Corporation: R&D Expenditure, 2018-2020
Figure 10.100: Vericel Corporation: SWOT Analysis
Figure 10.101: Zimmer Biomet Holdings, Inc.: Product Portfolio
Figure 10.102: Zimmer Biomet Holdings, Inc.: Overall Financials, 2018-2020
Figure 10.103: Zimmer Biomet Holdings, Inc.: Revenue (by Segment), 2018-2020
Figure 10.104: Zimmer Biomet Holdings, Inc.: Revenue (by Region), 2018-2020
Figure 10.105: Zimmer Biomet Holdings, Inc.: R&D Expenditure, 2018-2020
Figure 10.106: Zimmer Biomet Holdings, Inc.: SWOT Analysis
Report Description
|
Market Report Coverage - Regenerative Medicines |
|||
|
Base Year |
2019 |
Market Size in 2019 |
$21.59 Billion |
|
Forecast Period |
2020-2030 |
Value Projection and Estimation by 2030 |
$87.03 Billion |
|
CAGR During Forecast Period |
13.99% |
Number of Tables |
13 |
|
Number of Pages |
264 |
Number of Figures |
208 |
|
Research Hours |
240 |
|
|
|
Market Segmentation |
• Product – Tissue Engineering (Allogeneic Tissue, Autologous Tissue, Xenogeneic Tissue, and Synthetic Tissue), Stem Cells (Stem Cell Services and Stem Cell Therapies), and Cell ang Gene Therapy (Car-T Cell Therapy, Gene Therapy, Other Cell Therapies) • Application – Orthopedic and Musculoskeletal, Oncology, Wound Care, Cardiology, Immunology, Dermatology, and Other Applications |
||
|
Regional Segmentation |
• North America – U.S., and Canada • Europe – Germany, U.K., France, Italy, Spain, Netherlands, Russia, and Rest-of-Europe • Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific • Latin America – Brazil, Mexico, and Rest-of-Latin America • Rest-of-the-World |
||
|
Growth Drivers |
• Increasing Consolidation Among Healthcare Juggernauts • Rising Number of Clinical Trials for Regenerative Therapies • A Favorable Regulatory Environment to Accelerate Approvals and Market Entry • A Rising Awareness for Stem Cell Therapeutics |
||
|
Market Restraints |
• Lack of Reliable Vector Production for Cell and Gene Therapy • Exorbitant Cost of Next-Generation Therapies |
||
|
Market Opportunities |
• Drug Approvals and Strong Pipeline of Cell and Gene Therapies • Multiple Investments in Expansion of cGMP Units • Innovations in Regenerative Medicine |
||
|
Key Companies Profiled |
AbbVie, Inc., Baxter International Inc., Becton, Dickinson and Company, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Mesoblast Ltd., Novartis International A.G., NuVasive, Inc., Organogenesis Holdings, Inc., Smith & Nephew plc, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc. |
||
Key Questions Answered in this Report:
• What are the major market drivers, challenges, and opportunities and their respective impacts on the global regenerative medicines market?
• What is the potential impact of advancement in therapeutics among emerging segments of the global regenerative medicines market?
• What is the current market demand along with future demand for the global regenerative medicines market?
• What are the key regulatory hurdles for industry players looking to enter this highly dynamic market?
• What are the key development strategies that are implemented by the major players in order to sustain the competitive market?
• How is each of the segments of the market expected to grow during the forecast period from 2020 to 2030 based on each segment? Following are the segments:
o Product
o Application
o Regions, namely, North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW)
• Who are the leading players with significant offerings to the global regenerative medicines market? What is the expected market share for each of these leading players?
• Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global regenerative medicines market?
• How is the underlying cell and gene therapy segment pushing the boundaries of regenerative medicine across the world? What are the next-generation therapies within this segment?
Market Overview
BIS healthcare experts have found cell and gene therapy to be one of the most rapidly evolving and dynamic markets, and the global market for regenerative medicines is predicted to grow at a CAGR of 13.99% over the forecast period of 2020-2030. The market is driven by certain factors, including increasing consolidation among healthcare juggernauts, rising number of clinical trials for regenerative therapies, a favorable regulatory environment to accelerate approvals and market entry, and rising awareness for stem cell therapeutics, that are fueling the growth of the global regenerative medicines market.
Regenerative medicine is challenging the current healthcare practices by targeting the treatment of the root causes of disease and disorders, transforming it into an incredibly exciting space. However, these advancements have not come without significant challenges and uncertainties, which will also further need to be overcome to realize the full potential of regenerative medicine.
Cell and gene therapies, under the regenerative umbrella, are slowly and steadily becoming a healthcare standard, particularly in developed regions such as the U.S. and Europe, where already established markets for tissue engineering and stem cell have largely been responsible for driving the global regenerative medicine phenomenon. Cell and gene therapies, though advancing at a rapid pace, have primarily been targeted for hematological malignancies. However, the same potential has not been replicated in solid tumor applications, consequently creating demand for cell therapies focusing on solid tumors. As a result, the industry is now moving toward the research and subsequent clinical translation of next-generation therapies, led by natural killer (NK) cells, which offer a viable option for solid tumors as well. Such trends are consistently propelling the industry toward realizing the true potential of precision medicine.
Within the research report, the market is segmented on the basis of products, applications, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The global regenerative medicines market is currently witnessing several developments, primarily aimed toward bringing new products to support clinicians for the treatment of life-threatening disorders. Major manufacturers of regenerative medicine products are actively involved in undertaking significant business strategies in order to translate success in research and development into the commercial clinical setting. Although tissue engineering and stem cells remain the dominating product segments, the advent of cell and gene therapy has revolutionized the regenerative medicine phenomenon, moving it more toward the precision medicine space.
On the basis of region, North America holds the largest share of the regenerative medicines market due to a high number of active advanced therapeutic medicinal product trials, massive government funding, expansion activities by major companies, and an overall high adoption rate for advancing therapies. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2020-2030.
Global Regenerative Medicines Market
Focus on Products, Applications, 17 Countries’ Data and Competitive Landscape - Analysis and Forecast, 2020-2030
Some Faq's
Frequently Asked Questions
The global market for regenerative medicines generated $21.59 billion in 2019 and is projected to reach the value of $87.03 billion by 2030 with a CAGR of 13.99% during 2020-2030.
Several factors such as the increasing consolidation among healthcare juggernauts, rising number of clinical trials for regenerative therapies, and favorable regulatory environment to accelerate approvals and market entry, are driving the growth of this emerging technology market.
The lack of reliable vector production for cell and gene therapy, and exorbitant cost of next-generation therapies, hinder the growth curve of regenerative medicines market.
The North American region holds the largest share of the regenerative medicines market due to a high number of active advanced therapeutic medicinal product trials, massive government funding, expansion activities by major companies, and an overall high adoption rate for advancing therapies.
Some of the key players in the sectors are Baxter International Inc., Becton, Dickinson and Company, Gilead Sciences Inc., Medtronic PLC, Novartis International AG, Smith & Nephew PLC, and Stryker Corporation, among others.
Similar Product
You may also like
Published Year: 2021
Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional an
The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is...
Published Year: 2021
Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Coun
The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to...
Published Year: 2020
Global Bioengineered Skin Substitutes Market: Focus on Product Type, Application, End User, 4 Region
The global bioengineered skin substitutes market was valued at $1.31 billion in 2019 and is...